• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Liraglutide and systolic blood pressure.利拉鲁肽与收缩压
J Clin Hypertens (Greenwich). 2019 Jan;21(1):116-117. doi: 10.1111/jch.13443. Epub 2018 Dec 5.
2
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.利拉鲁肽在 2 型糖尿病中的临床应用及其对心血管危险因素的影响。
Endocr Pract. 2012 Mar-Apr;18(2):140-5. doi: 10.4158/EP11169.OR.
3
Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.度拉糖肽每周一次与利拉鲁肽治疗2型糖尿病患者的血糖控制及体重结局：一项1年回顾性队列分析
Clin Ther. 2016 Dec;38(12):2642-2651. doi: 10.1016/j.clinthera.2016.11.003. Epub 2016 Nov 23.
4
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.胰高血糖素样肽-1受体激动剂：临床实践中的实际考量
Diabetes Educ. 2015 Dec;41(1 Suppl):32S-46S. doi: 10.1177/0145721715607981. Epub 2015 Oct 8.
5
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的疗效与安全性：一项系统评价和混合治疗比较分析
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
6
[Not Available].[无可用内容]。
Ther Umsch. 2017;74(8):433-439. doi: 10.1024/0040-5930/a000937.
7
Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.利拉鲁肽单药治疗与磺脲类药物联合治疗对日本2型糖尿病患者安全性和有效性的回顾性分析：起始治疗一年后剩余β细胞功能与糖化血红蛋白（HbA1c）目标达成情况的关联
J Diabetes Complications. 2015 Nov-Dec;29(8):1203-10. doi: 10.1016/j.jdiacomp.2015.07.020. Epub 2015 Jul 21.
8
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.亚洲亚群可能从长效胰高血糖素样肽 1 受体激动剂中获得更大的心血管获益：心血管结局试验的荟萃分析。
Diabetes Metab J. 2019 Aug;43(4):410-421. doi: 10.4093/dmj.2018.0070. Epub 2018 Dec 27.
9
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.联合胰岛素和胰高血糖素样肽-1 治疗的长期疗效和安全性：来自 LEADER 试验的证据。
Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.
10
The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.胰高血糖素样肽-1类似物对肥胖的胰岛素治疗型2糖尿病患者饮食行为的影响。
Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23.

本文引用的文献

1
Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.2型糖尿病患者使用利拉鲁肽治疗时收缩压降低的预测因素及相关因素。
J Clin Hypertens (Greenwich). 2019 Jan;21(1):105-115. doi: 10.1111/jch.13447. Epub 2018 Dec 5.
2
Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery.减重手术后，脑啡肽酶和血管收缩剂减少，血管扩张剂增加。
Diabetes Obes Metab. 2018 Aug;20(8):2029-2033. doi: 10.1111/dom.13320. Epub 2018 May 2.
3
Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.艾塞那肽增加白细胞介素-1 受体拮抗剂浓度并诱导 Nrf2-Keap1 调控的抗氧化酶：与β细胞功能的相关性。
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1180-1187. doi: 10.1210/jc.2017-02343.
4
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.在 2 型糖尿病中使用抗糖尿病药物降低心血管风险：EMPA-REG OUTCOME、LEADER 和 SUSTAIN-6 试验主要心血管结局结果的综述。
Diabetes Care. 2017 Jul;40(7):821-831. doi: 10.2337/dc17-0291.
5
Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.艾塞那肽可诱导血管舒张介质增加，血管收缩介质减少。
Diabetes Obes Metab. 2017 May;19(5):729-733. doi: 10.1111/dom.12835. Epub 2017 Feb 22.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.在1型糖尿病患者中加用利拉鲁肽至胰岛素治疗：一项为期12周的随机安慰剂对照临床试验
Diabetes Care. 2016 Jun;39(6):1027-35. doi: 10.2337/dc15-1136. Epub 2016 Apr 5.
8
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.利拉鲁肽降低2型糖尿病患者收缩压：六项随机临床试验患者水平汇总分析的见解
J Diabetes Complications. 2014 May-Jun;28(3):399-405. doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21.
9
Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.利拉鲁肽作为胰岛素的附加治疗用于肥胖 1 型糖尿病患者。
Endocr Pract. 2013 Nov-Dec;19(6):963-7. doi: 10.4158/EP13065.OR.
10
Exenatide exerts a potent antiinflammatory effect.艾塞那肽具有强大的抗炎作用。
J Clin Endocrinol Metab. 2012 Jan;97(1):198-207. doi: 10.1210/jc.2011-1508. Epub 2011 Oct 19.

Liraglutide and systolic blood pressure.

作者信息

Dandona Paresh, Ghanim Husam, Chaudhuri Ajay

机构信息

Diabetes-Endocrinology Center of Western NY, Williamsville, NY.

State University of New York at Buffalo, Williamsville, NY.

出版信息

J Clin Hypertens (Greenwich). 2019 Jan;21(1):116-117. doi: 10.1111/jch.13443. Epub 2018 Dec 5.

DOI:10.1111/jch.13443
PMID:30515941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8030325/
Abstract
摘要